Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637946 | 0.86 | P2RX7 (0.56) | P2RX7HDAC1DRD2DRD3CYP11B2 | |
| SCHEMBL1635952 | 0.78 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL307940 | 0.73 | HDAC1 (0.45) | HDAC1MMP1MMP3MMP7MMP9 | |
| SCHEMBL1637578 | 0.72 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL26246206 | 0.72 | MMP2 (0.43) | MMP2ANPEPMMP1MMP3MMP7 | |
| SCHEMBL1635964 | 0.71 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL1637704 | 0.71 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL31647672 | 0.70 | KDM4E (0.56) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL16651888 | 0.70 | MMP2 (0.42) | P2RX7MMP2ANPEPMMP1MMP3 | |
| SCHEMBL1637480 | 0.70 | P2RX7 (0.53) | P2RX7DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932282-B2 | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| EP-2142512-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119825-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX5 | P2RX7 2/4885HDAC1 1558/4885MMP2 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.